Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure - Full Text View

Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure (CARNEBI)

This study is currently recruiting participants.

Verified by Centro Cardiologico Monzino, August 2007

First Received: August 16, 2007 No Changes Posted

Sponsor:	Centro Cardiologico Monzino
Information provided by:	Centro Cardiologico Monzino
ClinicalTrials.gov Identifier:	NCT00517725

Purpose

We test the hypothesis that different beta-blockers had a different influence on chemoreceptor response and lung diffusion capacity.

Both could influence exercise capacity in normoxic as well as hypoxic conditions.

Condition	Intervention	Phase
Chronic Heart Failure	Drug: carvedilol Drug: bisoprolol Drug: Nebivolol	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind (Investigator), Active Control, Crossover Assignment, Efficacy Study
Official Title:	Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure: Effects on Exercise Capacity and Hypoxia, Chemoreceptor Response, Pulmonary Function

Resource links provided by NLM:

MedlinePlus related topics: Exercise and Physical Fitness Heart Failure

Drug Information available for: Bisoprolol Carvedilol Nebivolol Bisoprolol fumarate

U.S. FDA Resources

Further study details as provided by Centro Cardiologico Monzino:

Primary Outcome Measures:

exercise capacity [ Time Frame: two months ]

Secondary Outcome Measures:

lung diffusion [ Time Frame: two months ]

Estimated Enrollment:	60
Study Start Date:	July 2007
Estimated Study Completion Date:	August 2009

Arms	Assigned Interventions
Carvedilol: Active Comparator	Drug: carvedilol
Bisoprolol: Active Comparator	Drug: bisoprolol
Nebivolol: Active Comparator	Drug: Nebivolol

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Chronic heart failure patients in stable clinical condition

Exclusion Criteria:

No comorbidity
NYHA class IV

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00517725

Contacts

Contact: Piergiuseppe Agostoni, MD, PhD

+39.025800 ext 2299

piergiuseppe.agostoni@ccfm.it

Locations

Italy
Centro Cardiologico Monzino, University of Milan	Recruiting
Milan, Italy, 20138
Contact: Piergiuseppe Agostoni, MD, PhD +39.025800 ext 2299 piergiuseppe.agostoni@ccfm.it

Sponsors and Collaborators

Centro Cardiologico Monzino

Investigators

Principal Investigator:	Piergiuseppe Agostoni, MD, PhD	Centro Cardiologico Monzino
Study Chair:	Giancarlo Marenzi, MD	Centro Cardiologico Monzino

More Information

Publications:

Agostoni P, Bussotti M, Cattadori G, Margutti E, Contini M, Muratori M, Marenzi G, Fiorentini C. Gas diffusion and alveolar-capillary unit in chronic heart failure. Eur Heart J. 2006 Nov;27(21):2538-43. Epub 2006 Oct 6.

Study ID Numbers:	R76-CCM S78/407
Study First Received:	August 16, 2007
Last Updated:	August 16, 2007
ClinicalTrials.gov Identifier:	NCT00517725 History of Changes
Health Authority:	Italy: Ministry of Health

Keywords provided by Centro Cardiologico Monzino:

exercise
lung diffusion
hypoxia

chemoreceptor
beta-blockers
heart failure

Additional relevant MeSH terms:

Vasodilator Agents
Sympatholytics
Heart Failure
Neurotransmitter Agents
Heart Diseases
Adrenergic Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Nebivolol
Adrenergic alpha-Antagonists
Cardiovascular Agents

Antihypertensive Agents
Pharmacologic Actions
Bisoprolol
Autonomic Agents
Therapeutic Uses
Adrenergic beta-Antagonists
Cardiovascular Diseases
Adrenergic Antagonists
Peripheral Nervous System Agents
Carvedilol

ClinicalTrials.gov processed this record on February 08, 2010